ETFELA

ETFELA
Clinical data
Other names	LA-CH2CF3
Identifiers
	IUPAC name (6aR,9R)-N-Ethyl-7-methyl-N-(2,2,2-trifluoroethyl)-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide;
CAS Number	3024529-99-2 ;
PubChem CID	163187757;
CompTox Dashboard (EPA)	DTXSID201337080 ;
Chemical and physical data
Formula	C20H22F3N3O
Molar mass	377.411 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCN(C(=O)[C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c[nH]3)CC(F)(F)F;
	InChI InChI=1S/C20H22F3N3O/c1-3-26(11-20(21,22)23)19(27)13-7-15-14-5-4-6-16-18(14)12(9-24-16)8-17(15)25(2)10-13/h4-7,9,13,17,24H,3,8,10-11H2,1-2H3/t13-,17-/m1/s1; Key:VAHPXTJQSWECIC-CXAGYDPISA-N;

ETFELA (N-ethyl-N-(2,2,2-trifluoroethyl)lysergamide) is an analog of lysergic acid diethylamide (LSD) first synthesised by Jason C. Parrish as part of the research team led by David E. Nichols. In studies in vitro, it was found to be slightly more potent than LSD itself.

Clinical data

Other names	LA-CH₂CF₃
Identifiers
IUPAC name (6aR,9R)-N-Ethyl-7-methyl-N-(2,2,2-trifluoroethyl)-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide
CAS Number	3024529-99-2^Y
PubChem CID	163187757
CompTox Dashboard (EPA)	DTXSID201337080
Chemical and physical data
Formula	C₂₀H₂₂F₃N₃O
Molar mass	377.411 g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES CCN(C(=O)[C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c[nH]3)CC(F)(F)F
InChI InChI=1S/C20H22F3N3O/c1-3-26(11-20(21,22)23)19(27)13-7-15-14-5-4-6-16-18(14)12(9-24-16)8-17(15)25(2)10-13/h4-7,9,13,17,24H,3,8,10-11H2,1-2H3/t13-,17-/m1/s1 Key:VAHPXTJQSWECIC-CXAGYDPISA-N